Long-term outcomes after cyclosporine or mycophenolate withdrawal in kidney transplantation - results from an aborted trial

Clinical Transplantation

Volumn 27, Issue 2, 2013, Pages

  Åsberg, Anders ^a   Apeland, Terje ^b   Reisæter, Anna V ^c   Foss, Aksel ^c   Leivestad, Torbjørn ^c   Heldal, Kristian ^d   Thorud, Lars O ^e   Eriksen, Bjørn O ^f   Hartmann, Anders ^c   Fauchald, Per ^c   Øien, Cecilia M ^g   Bjørneklett, Rune ^h   Høieggen, Aud ⁱ   Ganss, Rüdiger ^j  

^a UNIVERSITY OF OSLO   (Norway)

^b STAVANGER UNIVERSITY HOSPITAL   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d TELEMARK HOSPITAL   (Norway)

^e Innlandet Hospital Trust   (Norway)

^f UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^g TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^h HAUKELAND UNIVERSITY HOSPITAL   (Norway)

ⁱ ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^j AKERSHUS UNIVERSITY HOSPITAL   (Norway)

more..

Author keywords

Cyclosporine; Kidney transplantation; Long term outcome; Mycophenolate; Withdrawal

Indexed keywords

CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEATH; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LONG TERM CARE; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

ACUTE DISEASE; ADULT; AGED; CYCLOSPORINE; DRUG THERAPY, COMBINATION; EARLY TERMINATION OF CLINICAL TRIALS; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PREDNISOLONE; PROSPECTIVE STUDIES; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 84876092675     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12076     Document Type: Article

References (23)

1. Myers BD. Cyclosporine nephrotoxicity. Kidney Int 1986: 30: 964.
2. Remuzzi G, Bertani T. Renal vascular and thrombotic effects of cyclosporine. Am J Kidney Dis 1989: 13: 261.
3. Bennett WM, Houghton DC, Buss WC. Cyclosporine-induced renal dysfunction: correlations between cellular events and whole kidney function. J Am Soc Nephrol 1991: 1: 1212.
4. Smak Gregoor PJ, van Gelder T, van Besouw NM, van der Mast BJ, Ijzermans JN, Weimar W. Randomized study on the conversion of treatment with cyclosporine to azathioprine or mycophenolate mofetil followed by dose reduction. Transplantation 2000: 70: 143.
5. Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997: 63: 39.
6. Vajdic CM, McDonald SP, McCredie MR et al. Cancer incidence before and after kidney transplantation. JAMA 2006: 296: 2823.
7. Weir MR, Ward MT, Blahut SA et al. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int 2001: 59: 1567.
8. Sanders CE Jr, Curtis JJ. Role of hypertension in chronic renal allograft dysfunction. Kidney Int Suppl 1995: 52: S43.
9. Curtis JJ, Luke RG, Dubovsky E, Diethelm AG, Whelchel JD, Jones P. Cyclosporin in therapeutic doses increases renal allograft vascular resistance. Lancet 1986: 2: 477.
10. Mihatsch MJ, Ryffel B, Gudat F. The differential diagnosis between rejection and cyclosporine toxicity. Kidney Int Suppl 1995: 52: S63.
11. Solez K, Axelsen RA, Benediktsson H et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993: 44: 411.
12. English J, Evan A, Houghton DC, Bennett WM. Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function. Transplantation 1987: 44: 135.
13. Ojo AO, Meier-Kriesche HU, Hanson JA et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000: 69: 2405.
14. Schnuelle P, van Der Heide JH, Tegzess A et al. Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen. J Am Soc Nephrol 2002: 13: 536.
15. Smak Gregoor PJ, de Sevaux RG, Ligtenberg G et al. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. J Am Soc Nephrol 2002: 13: 1365.
16. Schrama YC, Joles JA, van Tol A, Boer P, Koomans HA, Hene RJ. Conversion to mycophenolate mofetil in conjunction with stepwise withdrawal of cyclosporine in stable renal transplant recipients. Transplantation 2000: 69: 376.
17. Thervet E, Morelon E, Ducloux D et al. Cyclosporine withdrawal in stable renal transplant recipients after azathioprine-mycophenolate mofetil conversion. Clin Transplant 2000: 14: 561.
18. Houde I, Isenring P, Boucher D, Noel R, Lachanche JG. Mycophenolate mofetil, an alternative to cyclosporine A for long-term immunosuppression in kidney transplantation? Transplantation 2000: 70: 1251.
19. McGrath JS, Shehata M. Chronic allograft nephropathy: prospective randomised trial of cyclosporin withdrawal and mycophenolate mofetil or tacrolimus substitution. Transplant Proc 2001: 33: 2193.
20. Mourer JS, Hartigh J, van Zwet EW, Mallat MJ, Dubbeld J, de Fijter JW. Randomized trial comparing late concentration-controlled calcineurin inhibitor or mycophenolate mofetil withdrawal. Transplantation 2012: 93: 887.
21. Le Meur Y, Buchler M, Thierry A et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007: 7: 2496.
22. van Gelder T, Le Meur Y, Shaw LM et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006: 28: 145.
23. van Gelder T, Silva HT, de Fijter JW et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation 1043: 2008: 86.